Skip to main content

Signal Genetics Debuts Array-Based Test for Multiple Myeloma

Premium

By Justin Petrone

Signal Genetics, a New York-based genetic testing firm, this month began offering the Myeloma Prognostic Risk Signature, or MyPRS, test, which was developed to help physicians guide treatment for individuals with multiple myeloma.

The firm is offering the test to physicians through a direct sales force and via select specialty commercial laboratories. The test, which is run on the Affymetrix GeneChip platform, will be performed at the company’s Clinical Laboratory Improvement Amendments-compliant laboratory in Little Rock, Ark., Signal said.

CEO Joe Hernandez said in a statement that MyPRS "uses the world’s largest outcomes database to correlate patient disease profiles, and provides additional insights to a patient’s specific gene expression profile." He said the firm's array-based gene expression test offers more detailed profiling information than the fluorescence in situ hybridization and cytogenetic-based assays that are currently on the market.

Signal acquired an exclusive license to the technology behind the new test from the University of Arkansas Medical Sciences earlier this year. The firm claims MyPRS can predict the stage of disease, calculate the odds of relapse, and lead physicians to the optimal treatment regimen for those suffering from myeloma.

In September, Signal said it would use the MyPRS testing platform in a multiple myeloma research program being conducted by Array BioPharma. Under the terms of that deal, Signal is providing Boulder, Colo.-based Array BioPharma with genetic information from patient samples in two upcoming clinical studies on an Array BioPharma drug candidate. It said at the time that the collaboration could lead to the development of "superior and personalized treatment options for myeloma patients."


Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.